Platform of Polymeric Conjugates
for Selective Intracorporeal Removal
of Specific Harmful Antibodies
RemAb Therapeutics is a biopharmaceutical company whose main activities and expertise are related, among others, to the identification, characterization and selective removal of specific antibodies (HART-Technology) for offering health solutions in the field of infectious diseases, allergology, autoimmunity, transplantation and transfusion medicine, and modulation of the human immune responses against viral vectors.
Harmful Antibody Removal Technology (HART)
We develop and optimize novel synthetic polymeric conjugates that bind to circulating harmful antibodies. The resulting immunocomplexes are rapidly cleared from circulation, delivering long-lasting therapeutical benefits for the patients.
How does HART work?
Presence of harmful antibodies
Identification of adverse circulating antibodies causing a deleterious immune response
Polymeric conjugate administration
RemAb develops injectable polymeric conjugates that bind to specific adverse antibodies
Polymeric conjugate antibody complex
Immunocomplexes are quickly metabolized and excreted
Clearance of Immunocomplexes
Rapid and safe clearance of immunocomplexes translates into immediate clinical benefits for the patients